Clinical Trials in Czechia — Country Dashboard | 1,513 EU Studies

Filter these 1,513 trials by condition, phase, sponsor and more.

Open in Search →

1,513 Registered trials

549 Recruiting

864 Completed trials

467 Sponsors active

568 Research sites

Phase III

Phase II

Phase III: 881 Phase II/III: 77 Phase II: 349 Phase I/II: 33 Phase III/IV: 13 Phase IV: 38 Phase I: 16 Phase I (Other): 40 Phase I (FiH): 14 Other: 52

Oversight events in trials active here:

67 serious breaches 465 temporary halts 21 urgent safety measures 48 unexpected events 73 corrective measures across 203 trials

View oversight register →

Top conditions

Non-small cell lung cancer 21 Crohn's disease 18 Prostate cancer metastatic 15 Colitis ulcerative 15 Pulmonary arterial hypertension 15 Asthma 14 Ovarian cancer 13 Systemic lupus erythematosus 12 Obesity 12 Multiple sclerosis 12 Dermatitis atopic 12 Diffuse large B-cell lymphoma 11

Top sponsors

Novartis Pharma AG 86 Merck Sharp & Dohme LLC 66 Janssen - Cilag International 58 Sanofi-Aventis Recherche & Developpement 54 AstraZeneca AB 50 AbbVie Deutschland GmbH & Co. KG 45 Pfizer Inc. 42 F. Hoffmann-La Roche AG 35 Bristol-Myers Squibb Services Unlimited Company 29 Boehringer Ingelheim International GmbH 28 Amgen Inc. 27 Eli Lilly & Co. 25

Cities with most trials

All 183 cities →

All trials — page 15

1,513 total

Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting

2024-512298-28-00 Phase III/IV Neovascular age-related macular degeneration AbbVie Deutschland GmbH & Co. KG
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics Recruiting

2024-519836-18-00 Phase III treatment-resistant schizophrenia (TRS) Newron Pharmaceuticals S.p.A.
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting

2025-520825-19-00 Phase III IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also kn… Takeda Development Center Americas Inc.
A randomized, placebo-controlled, double-blind clinical trial evaluating the safety and efficacy of parecoxib in hospitalized patients with … Recruiting

2024-519436-17-00 Phase II spontaneous subarachnoid hemorrhage Fakultni Nemocnice U Sv Anny V Brne
A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting

2024-512904-21-00 Phase II Migraine AbbVie Deutschland GmbH & Co. KG
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Phase III Hypertriglyceridemia (HTG) Arrowhead Pharmaceuticals Inc.
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 Phase III PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Gro… Relay Therapeutics Inc.
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting

2024-517136-21-00 Phase III Renal Cell Carcinoma Merck Sharp & Dohme LLC
A Phase 2 trial to investigate efficacy and safety of vipoglanstat in women with endometriosis Recruiting

2025-522452-16-00 Phase II Endometriosis related pain Gesynta Pharma AB
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Phase II/III Moderately to Severely Active Crohn's Disease Janssen Cilag International
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521710-25-00 Phase II Lewy Body Dementia Psychosis (LBDP) Acadia Pharmaceuticals Inc.
Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting

2025-521381-10-00 Phase III Moderately to Severely Active Ulcerative Colitis Janssen Cilag International
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Phase III Non-Small Cell Lung Cancer (NSCLC) Pfizer Inc.
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520612-34-00 Phase III Agitation Associated with Alzheimer’s Disease Bristol-Myers Squibb Services Unlimited Company
Effects of goal-directed fluid management guided by a non-invasive device on the incidence of postoperative complications in neurosurgery: a… Recruiting

2024-511153-21-00 Phase IV elective neurosurgery treating unspecified brain conditions Fakultni Nemocnice Brno
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Phase II Moderately to Severely Active Ulcerative Colitis Spyre Therapeutics Inc.
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious… Recruiting

2025-522347-18-00 Phase II Major Depressive Disorder (MDD), with or without Anxious Dis… Seaport Therapeutics Inc.
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting

2025-521920-31-00 Phase II Graves’ Disease Immunovant Sciences GmbH
A study to test whether BI 1815368 helps people with an eye condition called diabetic macular edema Recruiting

2024-520384-14-00 Phase II Centre-involved diabetic macular edema Boehringer Ingelheim International GmbH
A first-in-human study to learn how safe BAY 3713372 is and how it works in participants with MTAP-deleted solid tumors Recruiting

2025-520623-24-00 Phase I (FiH) MTAP-deleted Solid Tumors Bayer AG
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Phase III Mild to moderate Alzheimer’s Disease Bristol-Myers Squibb Services Unlimited Company
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Phase II Generalized Anxiety Disorder Intra-Cellular Therapies Inc.
A Study to Evaluate the Efficacy and Safety of Mezagitamab Subcutaneous Injection Compared With Placebo in Adults With Chronic Immune Thromb… Recruiting

2024-514401-54-00 Phase III Chronic Primary Immune Thrombocytopenia Takeda Development Center Americas Inc.
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting

2024-515979-35-00 Phase III Generalized Myasthenia Gravis Immunovant Sciences GmbH

Showing 337–360 of 1,513 trials

← All countries